News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Michael Rothenberg: A next generation BRAF Inhibitor shows promise in treatment refractory cancer patients
Photo taken from S. Michael Rothenberg/LinkedIn
Sep 9, 2024, 17:52

Michael Rothenberg: A next generation BRAF Inhibitor shows promise in treatment refractory cancer patients

Michael Rothenberg, Chief Medical Officer at I

“The Pfizer, Pfizer Boulder Research Unit, and academic collaborators’ clinical and translational work on PF-07799933 (ARRY-440) is out in the September issue of Cancer Discovery. A next-generation, brain-penetrant, pan-mutant BRAF-selective inhibitor, together with innovative and accelerated phase 1 clinical development with demonstrated efficacy in treatment-refractory cancer patients.”

A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation 

Authors: Rona Yaeger, Meredith A. McKean, Rizwan Haq, J. Thaddeus Beck, Matthew H. Taylor, Jonathan E. Cohen, Daniel W. Bowles, Shirish M. Gadgeel, Catalin Mihalcioiu, Kyriakos P. Papadopoulos, Eli L. Diamond, Keren B. Sturtz, Gang Feng, Stefanie K. Drescher, Micaela B. Reddy, Bhaswati Sengupta, Arnab K. Maity, Suzy A. Brown, Anurag Singh, Eric N. Brown, Brian R. Baer, Jim Wong, Tung-Chung Mou, Wen-I Wu, Dean R. Kahn, Sunyana Gadal, Neal Rosen, John J. Gaudino, Patrice A. Lee, Dylan P. Hartley, S. Michael Rothenberg

Michael Rothenberg: A next generation BRAF Inhibitor shows promise in treatment refractory cancer patients

Source: Michael Rothenberg/LinkedIn

Anurag Singh Arnab K. Maity Bhaswati Sengupta BRAF-selective inhibitor Brian R. Baer cancer Cancer Discovery Catalin Mihalcioiu Daniel W. Bowles Dean R. Kahn Dylan P. Hartley Eli L. Diamond Eric N. Brown Gang Feng J. Thaddeus Beck Jim Wong John J. Gaudino Jonathan E. Cohen Keren B. Sturtz Kyriakos P Papadopoulos Matthew H. Taylor Meredith A. McKean Micaela B. Reddy Michael Rothenberg Neal Rosen OncoDaily Oncology Patrice A. Lee Rizwan Haq Rona Yaeger S. Michael Rothenberg Shirish M. Gadgeel Stefanie K. Drescher Sunyana Gadal Suzy A. Brown Tung-Chung Mou Wen-I Wu
Special Coverage
Blog
Apr 19, 2025, 18:05
Prasad Raj Dandekar: A detailed conversation about immunotherapy with Sewanti Limaye
Blog
Apr 19, 2025, 17:53
Cancer Nutrition Tips: Pink Africa Foundation Highlights Healing Benefits
Blog
Apr 19, 2025, 17:21
Exploring the integration of patient-reported outcome measures in clinical practice
Blog
Apr 19, 2025, 17:17
Join our Networks and Working Groups to learn, network and grow - SIOP
Blog
Apr 19, 2025, 17:14
Re-irradiation revolution: Maximising technical advances in imaging, biology and dose evaluation at ESTRO 2025
Blog
Apr 19, 2025, 17:02
New whitepaper on navigation services and reimbursement success - Florida Cancer Specialists and Research Institute
Blog
Apr 19, 2025, 17:01
Chiara Mercinelli: Honored to have been selected for the ASCO 2025 Merit Award
Blog
Apr 19, 2025, 16:48
How EveryGrant helps organizations build impactful grant programs - Conquer Cancer, the ASCO Foundation
Blog
Apr 19, 2025, 16:44
Agenus to Reveal Phase 1 HCC Immunotherapy Data at AACR 2025
Blog
Apr 19, 2025, 16:36
Bilal Awad: Knowledge, attitudes, and self-efficacy regarding palliative care among Palestinian nurses in intensive care units
Blog
Apr 19, 2025, 16:23
Toufic Kachaamy: Thrilled to give two talks on cancer ablation at DDW2025
Blog
Apr 19, 2025, 16:23
Elvina Almuradova: Olaparib improved ORR and PFS in BRCA-mutated PSR ovarian cancer, but no OS benefit